EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma

BMC Cell Biology

Longjiang Li³  Zhuoyuan Zhang⁴  Yichao Xia⁴  Chunjie Li⁴  Ying Liu⁴  Jiao Chen⁴  Xiaoyue Fu²  Tao Yu¹  Yi Huang⁴ 

[1] Department of Head and Neck Oncology, Sichuan Cancer Hospital, No. 55, Sec. 4, Renminnan Road, Chengdu, Sichuan, 610041, People’s Republic of China;Department of Thoracic Cancer, West China Hospital of Sichuan University, Chengdu, China;Department of Head and Neck Oncology, West China College of Stomatology, Sichuan University, No.14, Section 3, Ren Min Nan Road, Chengdu, 610041, China;State Key Laboratory of Oral Diseases, West China Collegel of Stomatology, Sichuan University, Chengdu, China

关键词: Cancer therapy;    Invasion;    Epithelial- mesenchymal transition (EMT);    Matrix metalloproteinase (MMP);    Monoclonal antibody;    Nimotuzumab;    Adenoid cystic carcinoma (ACC);    Epidermal growth factor receptor (EGFR);   

Others  :  855438
DOI  :  10.1186/1471-2121-14-13

 received in 2012-06-27, accepted in 2013-01-08,  发布年份 2013

【 摘 要 】

Background

Epidermal growth factor receptor (EGFR) is involved in the development of many human malignant tumors and plays an important role in tumor growth and metastasis. Antagonists of EGFR can suppress the growth of several malignancies; however, their therapeutic effect in adenoid cystic carcinoma (ACC) is controversial.

Results

The increased proliferation of two ACC cell lines induced by EGF-treatment was reversed by nimotuzumab. Regardless of EGF stimulation, nimotuzumab-treated ACC cells were arrested in G1 phase and showed decreased expression of Ki67. In addition, EGF activated the MAPK-dependent pathway and up-regulated the expression of matrix metalloproteinase-9 and Snail, enhancing the invasive potential of an ACC cell line (ACC-M). The effects of EGF were down-regulated by nimotuzumab treatment.

Conclusions

These results suggest that nimotuzumab can inhibit the growth and invasion of ACC cells induced by EGF, probably through inactivation of ERK phosphorylation. Thus, nimotuzumab should be considered as a promising novel agent for the treatment of ACC.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jaso J, Malhotra R: Adenoid cystic carcinoma. Arch Pathol Lab Med 2011, 135:511-515.
• [2]Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M: Activation of the osteopontin/ matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008, 14:7470-7480.
• [3]Fromigué O, Hamidouche Z, Marie PJ: Blockade of the RhoA-JNK-c-Jun- MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008, 283:30549-30556.
• [4]Culhaci N, Metin K, Copcu E, Dikicioglu E: Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 2004, 4:42-49. BioMed Central Full Text
• [5]Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
• [6]Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, Krengel U, Moreno E: Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009, 69:5851-5859.
• [7]Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A: Use of the humanized anti- epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-1654.
• [8]Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS: Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009, 1:41-48.
• [9]Vered M, Braunstein E, Buchner A: Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002, 24:632-636.
• [10]Kudo M, Ishiwata T, Nakazawa N: Keratinocyte growth factor- transfection- stimulated adhesion of colorectal cancer cells to extracellular matrices. Exp Mol Pathol 2007, 83:443-452.
• [11]Tang Y, Liang X, Zheng M, Zhu Z, Zhu G, Yang J, Chen Y: Expression of c-kit and slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. Oral Oncol 2010, 46:311-316.
• [12]Chandler HL, Colitz CM, Lu P, Saville WJ, Kusewitt DF: The role of the slug transcription factor in cell migration during corneal re-epithelialization in the dog. Exp Eye Res 2007, 84:400-411.
• [13]Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of snail by NF-kB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428.
• [14]Maruyama S, Cheng J, Yamazaki M, Zhou XJ, Zhang ZY, He RG, Saku T: Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems. Cancer Genet Cytogenet 2010, 196:14-22.
• [15]Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z: Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol 2010, 41:1617-1623.
• [16]Reuter CW, Morgan MA, Eckardt A: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007, 96:408-416.
• [17]Li X, Huang Y, Jiang J, Frank SJ: Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors. Cell Signal 2011, 23:417-424.
• [18]Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002, 101:567-575.
• [19]Karatzas A, Katsanos K, Maroulis I, Kalogeropoulou C, Tzorakoleftherakis E, Karnabatidis D: Multi-modality curative treatment of salivary gland cancer liver metastases with drug-eluting bead chemoembolization, radiofrequency ablation, and surgical resection: a case report. J Med Case Reports 2011, 5:416-421. BioMed Central Full Text
• [20]Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE: Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 2004, 33:25-31.
• [21]Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, Douzinas EE, Patsouris E: Adenoid cystic carcinoma of the head and neck: clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 2005, 41:328-335.
• [22]Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006, 42:759-769.
• [23]Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011, 12:815-824.
• [24]Ribatti D: Antiangiogenic therapy accelerates tumor metastasis. Leuk Res 2011, 35:24-26.
• [25]Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK, Myers JN: Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2008, 14:5081-5089.
• [26]Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5- year survival data from a phase 3 randomised trial, and relation between cetuximab- induced rash and survival. Lancet Oncol 2010, 11:21-28.
• [27]Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L: CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 2011, 9:161-172.